Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Garber

Showing results (11-20 of 393) with videos related to

Pageof 40
Sort By:
Diabetes, Obesity & Metabolism|November 15, 2011
Obesity and type 2 diabetes: which patients are at risk?A J Garber
Diabetes, Obesity & Metabolism|March 13, 2012
Liraglutide in oral antidiabetic drug combination therapyA J Garber
Diabetes, Obesity & Metabolism|November 1, 2014
What is the best approach to glycaemic control in patients with type 2 diabetes?A J Garber
International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity|November 4, 2000
The importance of early insulin secretion and its impact on glycaemic regulationA J Garber
American Family Physician|January 6, 2001
Attenuating cardiovascular risk factors in patients with type 2 diabetesA J Garber
American Family Physician|March 2, 2006
New standards to reduce morbidity and mortality in hospitalized patients with diabetesAlan J Garber
Clinical Therapeutics|March 8, 2006
Assessing the role of biphasic insulin aspart 30 as an effective and tolerable front-line therapy for type 2 diabetesAlan J Garber
Diabetes Care|October 31, 2009
Combined pharmacologic/nonpharmacologic intervention in individuals at high risk of developing type 2 diabetes: pro pharmacologic therapyAlan J Garber
Diabetes, Obesity & Metabolism|March 2, 2013
Methods to enhance delivery of prandial insulin and basal-prandial insulinA J Garber
The Lancet. Diabetes & Endocrinology|April 8, 2014
GLP-1 receptor agonists: why is once weekly inferior to once daily?Alan J Garber
Pageof 40

Showing results (11-20 of 393) with videos related to

Sort By:
Pageof 40
Diabetes, Obesity & Metabolism|November 15, 2011
Obesity and type 2 diabetes: which patients are at risk?A J Garber
Diabetes, Obesity & Metabolism|March 13, 2012
Liraglutide in oral antidiabetic drug combination therapyA J Garber
Diabetes, Obesity & Metabolism|November 1, 2014
What is the best approach to glycaemic control in patients with type 2 diabetes?A J Garber
International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity|November 4, 2000
The importance of early insulin secretion and its impact on glycaemic regulationA J Garber
American Family Physician|January 6, 2001
Attenuating cardiovascular risk factors in patients with type 2 diabetesA J Garber
American Family Physician|March 2, 2006
New standards to reduce morbidity and mortality in hospitalized patients with diabetesAlan J Garber
Clinical Therapeutics|March 8, 2006
Assessing the role of biphasic insulin aspart 30 as an effective and tolerable front-line therapy for type 2 diabetesAlan J Garber
Diabetes Care|October 31, 2009
Combined pharmacologic/nonpharmacologic intervention in individuals at high risk of developing type 2 diabetes: pro pharmacologic therapyAlan J Garber
Diabetes, Obesity & Metabolism|March 2, 2013
Methods to enhance delivery of prandial insulin and basal-prandial insulinA J Garber
The Lancet. Diabetes & Endocrinology|April 8, 2014
GLP-1 receptor agonists: why is once weekly inferior to once daily?Alan J Garber
Pageof 40